Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevos métodos de detección de reacción en cadena de la polimerasa múltiple (PCR) para analizar enfermedades infecciosas y detectar mutaciones cancerosas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20160711001
Publicado:
14/07/2016
Caducidad:
14/07/2017
Resumen:
Una pyme británica ha desarrollado un nuevo método de detección con múltiples aplicaciones en diagnóstico médico. Con este método es posible la detección de múltiples objetivos en un solo análisis utilizando instrumentos estándar, permitiendo la detección múltiple de más objetivos en una sola reacción en tubo cerrado que lo que es posible actualmente. La empresa busca compañías/instituciones con el fin de establecer acuerdos de licencia y comercialización o continuar con el desarrollo mediante acuerdos de cooperación o comercialización con asistencia técnica.

Details

Tittle:
Novel multiplex polymerase chain reaction (PCR) detection methods for infectious disease testing and cancer mutation detection
Summary:
A UK SME has developed a novel detection method which has multiple possible applications in medical diagnostics. The method allows the detection of multiple targets in a single analysis using current standard instrumentation, enabling multiplex detection of more targets in a single closed-tube reaction than currently possible. The company seeks companies/institutions for licensing -Y- marketing opportunities, or for co-development via technical or commercial agreement with technical assistance.
Description:
The company has developed several patented technologies in the fields of multiplex real-time PCR and Next Generation Sequencing, and has CE IVD (In-Vitro Diagnostic Medical Devices) products in the market.

·MPA (Multiplex Probe Amplification) is a platform real-time PCR-based technology allowing detection and genotyping of up to 20 different targets in a single closed-tube reaction, significantly increasing throughput capabilities. Papilloplex HR-HPV Genotyping Assay is a CE IVD marked product for detection, differentiation and quantitation of all 14 high-risk HPV types in a single analysis.

·MMD-PCR (Multiplex Mutation Detection) is technology for cancer gene mutation detection. It has features: detection of multiple mutations in a single analysis; reduced reaction tubes to preserve clinical material, save reagents and allow high-throughput; sensitive simple real-time PCR reaction; internal endogenous control to further reduce the number of reactions required.

·TBD-seq (Tagged BiDirectional Sequencing) is a sensitive next generation sequencing technology, which is well suited to detecting ultra-rare cancer gene mutations in the blood.

They are seeking companies or research centres to co-develop the products via commercial agreements with technical assistance or technical cooperation agreements, or to license the technologies.
Advantages and Innovations:
Multiplex real-time PCR offers numerous advantages, including time savings, elimination of contamination risk, reduced reagent costs, increased throughput, conservation of precious sample material and reliable results. However, current probe-based methods allow detection of only one target sequence per fluorescence channel. The multiplex fluorescent PCR is therefore limited by the availability of fluorescence dyes and channels; up to five or six targets, depending on particular PCR machines, can be detected simultaneously in the current platforms.

This technology inherits all the benefits of the traditional TaqMan-based real-time PCR at the same time offering several advantages due to its increased multiplexing capabilities:

- increased speed of analysis
- reduced quantity of staring material
- reduced risk of contamination
- reduced overall costs as more targets are analyzed with the same amount of reagents
Stage of Development:
Already on the market
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
The patents have been granted in Europe, US, China, pending in Japan, Canada, Australia

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: companies or research institutions
- Specific area of activity of the partner: development of novel diagnostic applications
- Task to be performed by the partner sought: co-development of technology to new applications via commercial agreement with technical assistance, or technical cooperation agreements or licensing of existing technology

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
Chinese
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001005 Diagnósticos, diagnosis
06002007 Ensayos in vitro, experimentos